CFRXQ — CONTRAFECT Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: ContraFect Reports Q1 Loss Per Share $0.51
ContraFect Corp expected to post a loss of 31 cents a share - Earnings Preview
ContraFect Corp reports results for the quarter ended in December - Earnings Summary
Brief: Contrafect Reports Q4 Loss Per Share $0.11
Brief: ContraFect Announces Award From Cystic Fibrosis Foundation To Evaluate Exebacase As A Potential Treatment For Serious MRSA Lung Infections Associated With Cystic Fibrosis
Brief: ContraFect Files For Offering Of 8.8 Mln Shares Of Common Stock
U.S. RESEARCH ROUNDUP-Coresite Realty, Hanmi Financial, Y-Mabs Therapeutics
ContraFect Corp reports results for the quarter ended in September - Earnings Summary
Brief: ContraFect Reports Q3 Loss Per Share $0.13
ContraFect Corp expected to post a loss of 28 cents a share - Earnings Preview
ContraFect Corp expected to post a loss of 28 cents a share - Earnings Preview
Brief: ContraFect's New Phase 2 Exebacase Data Presented At Idweektm Demonstrates Rapid Symptom Resolution Among Patients With Staphylococcus Aureus Bacteremia
ContraFect Corp expected to post a loss of 28 cents a share - Earnings Preview
Brief: ContraFect Announces Multiple Publications On CF-296 Showing Potent In Vivo Antimicrobial Activity
ContraFect Corp reports results for the quarter ended in March - Earnings Summary
ContraFect Corp expected to post a loss of 22 cents a share - Earnings Preview
Brief: ContraFect Corp Reports Q1 Loss Per Share Of $0.18
Brief: ContraFect Corp Announces Issuance Of Composition Of Matter Patent For Cf-370 By United States Patent And Trademark Office
Brief: Contrafect Reports Q4 Loss Per Share $0.23